Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed adenocarcinoma of the pancreas
• * Advanced disease
• No standard curative therapy available
• Must have received prior first-line chemotherapy
• No brain metastasis
• PATIENT CHARACTERISTICS:
• WHO performance status 0-2
• Life expectancy ≥ 8 weeks
• ANC ≥ 1.5 x 10\^9/ L
• Platelet count ≥ 130 x 10\^9/ L
• Hemoglobin ≥ 10 g/dL
• Liver transaminases ≤ 1.5 times upper limit of normal (ULN) (≤ 5 times ULN in the presence of liver metastases)
• Bilirubin ≤ 1.5 times ULN
• Creatinine ≤ 130 mmol/L OR creatinine clearance \> 30 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No intolerance or hypersensitivity to any of the drugs being tested
• No history of interstitial lung disease
• No history of severe cardiac disease
• No serious uncontrolled infection
• No rare hereditary disorders, i.e., galactosemia, lactase deficiency, or malabsorption of glucose or galactose syndrome
• Must not be deprived of liberty or under guardianship
• Must not be on probation
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior erlotinib hydrochloride
• No concurrent potent inducers or inhibitors of cytochrome P450 or CYP3A4
• More than 14 days since participation in another clinical trial